Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-13 · accession 0001539937-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-03-16 | 2026-03-13 | SUPN | Khattar Jack A. | Pres, CEO, Dir | S - Sale | $50.37 | -35.0K | 969.0K | -3% | -$1.76M |
| I | 2026-03-16 | 2026-03-13 | SUPN | Khattar Jack A. | Pres, CEO, Dir | J - Other | — | -12.5K | 993.1K | -1% | — |
| 2026-03-16 | 2026-03-13 | SUPN | Khattar Jack A. | Pres, CEO, Dir | J - Other | — | +12.5K | 1.24M | +1% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-13 | S | D | 120 | $51.75 | 958,100 | I | — | — | |
| 2 | Common | Common Stock | 2026-03-13 | S | D | 10,742 | $51.00 | 958,220 | I By the KBT Trust | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $51.54. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 3 | Common | Common Stock | 2026-03-13 | J | D | 12,500 | — | 993,100 | I By the KBT Trust | — | — | (F1) The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly. |
| 4 | Common | Common Stock | 2026-03-13 | J | A | 12,500 | — | 1,241,144 | D By the KBT Trust | — | — | (F1) The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly. |
| 5 | Common | Common Stock | 2026-03-13 | S | D | 24,138 | $50.09 | 968,962 | I By the KBT Trust | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.63 to $50.62. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |